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Abstract
Introduction: Intramuscular myxoma is a rare benign soft tissue tumor. The lack of specific symptoms and widely
used laboratory tests makes the diagnosis quite difficult. We present a case of an Intramuscular myxoma associated
with an increased carbohydrate antigen 19.9 level. To the best of our knowledge, there have not been any
reported cases of an association of Intramuscular myxoma with tumor markers in the literature.
Case presentation: A 45-year-old Caucasian woman presented to our department for resection of a mass in her
left groin area, discovered incidentally on a triplex ultrasonography of her lower extremities. The diagnosis of
Intramuscular myxoma was confirmed on histopathology after the complete surgical excision of the tumor. On
laboratory examination, the serum level of carbohydrate antigen 19.9 was found to be elevated, but it returned to
normal six months after resection of the mass.
Conclusion: Carbohydrate antigen 19.9 is a tumor marker that increases in a variety of malignant and benign
conditions. After the exclusion of all other possible reasons for carbohydrate antigen 19.9 elevation, we assumed a
possible connection of carbohydrate antigen 19.9 elevation and Intramuscular myxoma, an issue that requires
needs further investigation.
Introduction
Intramuscular myxoma (IM) is a rare benign soft tissue
tumor that presents as a slowly growing, deeply seated
mass confined to the skeletal muscle. IM has an inci-
dence of 0.1 to 0.3 per 100,000 [1]. According to the
World Health Organization, IM is classified as a tumor
of uncertain differentiation [2]. The symptoms, if any, are
usually vague. The only widely available diagnostic tests
are imaging studies, such as ultrasonography, computed
tomography (CT), and magnetic resonance imaging
(MRI), which reveal a mass but cannot differentiate. The
definite diagnosis of IM can only be made after its surgi-
cal excision, which is also agreed to be the treatment of
choice [3].
We present the case of a 45-year-old Caucasian
woman with an IM in her left groin area. It was
diagnosed on histopathology after its complete excision.
Pre-operative screening revealed an elevated carbohy-
drate antigen (CA) 19.9 level, which returned to normal
six months after the surgical excision. To the best of
our knowledge, an association of CA 19.9 with the diag-
nosis of an IM has not previously been considered. This
hypothesis is presented after the exclusion of all other
possible causes along with a brief review of the
literature.
Case presentation
A 45-year-old Caucasian woman was admitted to our
surgical department for treatment of a mass in her left
groin area. From her past medical history, our patient
was on treatment with levothyroxine after thyroidect-
omy for multi-nodular goiter and with amlodipine and
valsartan for hypertension. She did not smoke cigarettes
and did not report any history of trauma in the area.
The mass was discovered incidentally on a lower
extremity triplex ultrasonography one month before her
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admission. Our patient was complaining of aching, sore-
ness and heaviness of her lower extremities for two
months and was advised to have her lower extremity
venous system evaluated. On her right lower extremity,
the triplex ultrasonography revealed insufficiency of the
saphenofemoral junction and insufficient valves of the
great saphenous vein. On her left lower extremity, the
study was difficult to perform because of a mass in the
groin area. It was a solid hypoechoic mass of heteroge-
neous texture, 50×55 mm in size, lying 11 mm under
the skin surface and with minimal blood flow. It
appeared to be in proximity with the femoral vessels but
without compressing them, and there was no local
lymph node enlargement.
On physical examination, a painless, fixed, solid mass
was palpated in her left groin area. Both lower limbs
were symmetrical with normal motility.
Our patient was subsequently submitted for an MRI of
the area. It revealed a mass lying in a space defined ante-
riorly from her pectineus muscle, posteriorly from her
abductor muscle, laterally from her obturator muscle and
medially from her innominate bone. The mass had a het-
erogeneous low signal intensity on T1-weighted images
and heterogeneous high signal intensity with inner areas
of low signal intensity on T2-weighted images. It was
lobulate with dimensions 78×59×45 mm and relatively
well-defined margins. No enhancement was marked after
the intravenous administration of paramagnetic sub-
stance (Figures 1 and 2). Additional imaging studies
(upper and lower abdominal ultrasonography, chest
radiography) did not reveal any other pathology.
On laboratory examination, a full blood count, basic
metabolic panel, liver and kidney function tests, electro-
lytes and amylase, and coagulation profile were normal.
The thyroid function tests showed euthyroidism. Can-
cer- and tissue-specific markers (a-fetoprotein, carci-
noembryonic antigen, CA 15.3, CA 19.9 and CA 125)
were also tested. Of these, CA 19.9 was found elevated
at 39.51 U/mL (reference range, 0-35 U/mL). To
exclude possible laboratory error, the elevated value of
CA 19.9 was repeated twice.
Our patient underwent a surgical excision of the mass.
A longitudinal incision over the femoral vessels was per-
formed, and a mass measuring approximately 6 cm was
identified. It was firmly attached to the adjacent struc-
tures; however, it was dissected without ligating any
large blood vessel. The mass was resected en bloc and
sent for histopathology study. The incision was closed
with interrupted sutures.
The post-operative period was uneventful, and our
patient was discharged on the third post-operative day.
The macroscopical specimen examination revealed an
oval-shaped lobulated mass 80× 55×50 mm in size with
residual striated muscle. On histopathology, it was
found to be an IM.
At the follow-up six months later, our patient did not
have any complaints, and there was no clinical evidence
of recurrence. Ultrasonography of her left groin area
revealed insufficiency of the saphenofemoral junction
and no mass recurrence. Upper and lower abdominal
ultrasonography results were normal. All laboratory test
results were normal, and CA 19.9 was reduced to 11.34
U/mL. During colonoscopy, the sigmoid colon was
Figure 1 Coronal T2-weighted MRI of left groin Intramuscular
myxoma.
Figure 2 Axial T1-weighted MRI of left groin Intramuscular
myxoma.
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found to be edematous and spastic, and first-grade
hemorrhoid disease was present.
Discussion
IM is a rare entity. Virchow introduced the term myx-
oma in 1863 to describe a tumor that in histology
resembles the umbilical cord [4]. The initial criteria for
diagnosis of myxoma was established by Stout in 1948
when he stated that myxoma is a true mesenchymal
neoplasm composed of undifferentiated stellate cells in a
myxoid stroma [4]. It is still not clarified if IM is a
benign soft tissue tumor or a reactive proliferation of
hypersecretory fibroblasts [5].
The majority of IMs appear from the fourth to sixth
decades of life, with a slight predominance in women
(male:female ratio, 1:1.4) [4]. It usually arises from large
skeletal muscles, so the commonest location is the lower
extremities, particularly the thigh (51%) and the gluteal
area (7%) [4,6]. IMs can measure up to 20 cm; however,
they usually measure 5 to 10 cm [6]. The majority of
IMs appear as a single mass. If multiple, they are asso-
ciated with fibrous dysplasia of the bones of the same
extremity, known as Mazabraud syndrome [6,7].
The vast majority of patients are asymptomatic, and
the myxoma appears as a painless, slowly enlarging,
palpable, well-defined, round-shaped mass [4].
The current modes of imaging IMs are ultrasonogra-
phy, CT and MRI. On ultrasonography, IM appears as a
heterogeneous hypoechoic relative to skeletal muscle
mass, with well-defined margins. IM usually does not
appear capsulated, but sometimes it can have a partial
or complete capsule [4]. Before the administration of
intravenous contrast, CT reveals a mass of low attenua-
tion (less than that of the muscle), with almost equal
appearance of homo- and heterogeneous texture [4].
After the administration of intravenous contrast, CT
images reveal an equal percentage of mild enhancement
and of absence of enhancement [4]. MRI shows low sig-
nal intensity on T1-weighted images and high signal
intensity on T2-weighted images, with peripheral or pat-
chy enhancement after injection of gadolinium [4]. CT
and MRI may reveal surrounding muscle edema [4].
The treatment of IM is its surgical excision with a
wide local excision, and has an excellent prognosis [3].
After the resection of the mass, recurrence can occur in
fewer than 5% of cases [3]. Recurrence may be attributa-
ble to insufficient resection of the tumor [3].
Recent studies show that the detection of GNAS1
mutations has an increased specificity in the diagnosis
of IM [8], although testing for GNAS1 mutations is not
commonly applicable. This makes the diagnosis of IMs
difficult before surgical excision.
On histology, IM demonstrates a hypocellular and
hypovascular appearance composed of fibroblasts
embedded in an abundant myxoid matrix [2]. The abun-
dant myxoid stroma consists of two main macro-mole-
cules: polysaccharide glycosaminoglycans and fibrous
structural proteins [9]. However, in some cases of IM,
areas of increased cellularity and vascularity can be
recognized [5]. This finding does not affect the benign
behavior of IM but can mislead clinicians into diagnos-
ing it as myxoid sarcoma [5]. In IM, the mitotic activity
is practically absent [6]. On cytopathology, IM usually
consists of bland spindle cells [2]. Immunohistology
shows expression of vimentin and a myxoid material
which is entirely digestible by hyaluronidase [3]. IM
shows no reactivity for S-100 protein, unlike myxoid
liposarcoma [3].
The differential diagnosis of IM includes myxoid lipo-
sarcoma, myxofibrosarcoma, myxoid chondrosarcoma,
leiomyosarcoma, embryonal rhabdomyosarcoma, neuro-
fibroma, nerve sheath myxoma or neurothekeoma, syno-
vial sarcoma, aggressive angiomyxoma, dermoid and
epidermoid cyst, lipoma, neuroma and ganglioma
[1,3,4,6,9].
CA 19.9, also known as sialylated Lewis a-antigen (a
blood protein in red blood cells), is an antigen defined
by the monoclonal antibody 1116NS 19.9. It was first
mentioned by Koprowski et al. in 1979 [10]. It is synthe-
sized by normal human pancreatic and biliary ducts and
by gastric, colonic, endometrial, salivary and bronchial
epithelium. CA 19.9 is considered to be the best serum
tumor marker for pancreatobilliary cancer and colorectal
cancer. Its reference range is usually 0 to 37 U/mL. CA
19.9 has a 70% to 90% sensitivity and 80% to 90% speci-
ficity in detecting pancreatobiliary cancer [10]. Its posi-
tive predictive value is 69%, and its negative predictive
value is 90% for the detection of pancreatobilliary cancer
[10]. False-positive results (31%) have been associated
with other pancreatobilliary disorders (for example, gall-
stones, pancreatitis, cystic fibrosis), inflammatory bowel
disease, duodenum ulcer, gastric and colonic polyps, dia-
betes mellitus, thyroid-related disorders (for example,
hypothyroidism), liver disease (for example, hepatitis,
alcoholic and non-alcoholic liver disease, polycystic liver
disease), splenic cyst, pulmonary problems (for example,
pneumonia, bronchogenic cyst, interstitial pulmonary
disease), kidney problems (for example, hydronephrosis,
renal cyst), collagen vascular disease, female reproduc-
tive system disease (for example, endometriosis) and
even heavy tea consumption [11].
Our patient was diagnosed with an IM, which was
fully resected and had no evidence of recurrence at fol-
low-up six months later. Although it appears to be a
typical presentation of IM, the elevated CA 19.9 level,
which returned to normal values six months after the
resection, was challenging. For this reason, we searched
for other possible causes of CA 19.9 elevation, and we
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submitted our patient to a number of imaging and
laboratory studies to rule out other possible diagnoses.
Our patient did not refer to any symptoms related to
conditions that elevate CA 19.9, and the commonest
types of malignancy that cause this elevation were
excluded. Pancreatobilliary and colon malignancies
could not be the cause because upper abdominal ultra-
sonography and colonoscopy results were normal. We
also excluded the possibility of benign diseases affecting
the liver, pancreas, gallbladder, kidneys, reproductive
system, colon and lungs to be the cause of this elevation
because upper and lower abdominal ultrasonography,
colonoscopy and chest radiography did not reveal any
pathology. An increase in CA 19.9 values has also been
associated with hypothyroidism [12], but this elevation
does not affect euthyroid patients [12]. In our case, our
patient was euthyroid before and after the surgical exci-
sion, and hypothyroidism was also excluded as a possi-
ble reason of CA 19.9 elevation. Taking these into
consideration, we assumed that our case could be indi-
cative of an association between CA 19.9 and IM
because normal values were restored after the resection.
To the best of our knowledge, there has been no pre-
viously reported association of serum tumor markers
with IM [6].
Conclusion
IM is a benign soft tissue tumor with an excellent prog-
nosis after its surgical excision. CA 19.9 is a tumor mar-
ker associated with malignancies of the pancreatobilliary
and colonic tract and with a multitude of benign condi-
tions. Our case raises the question of whether CA 19.9
is also associated with IM and indicates the need for
more data to be collected toward this direction.
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